Single-use Mini Scale Bioreactor Technology

Rubrik: Biotechnologie

(Treffer aus TechnoPharm, Nr. 06, Seite 320 (2016))

Ngibuini M

Single-use Mini Scale Bioreactor Technology / How it Enables Higher Productivity of Protein-based Therapeutics in the Pharmaceutical Industry · Ngibuini M · Sartorius Stedim Biotech, Royston (UK)
Biologics Bioprocess Bioreactor Fermentation Single-use Cell culture Monoclonal antibody Worldwide sales of biologic drugs including monoclonal antibodies (mAbs) exceed 120 billion US dollars per year [ 1 ]. With sales of around 50 billion US dollars, mAbs are the most widely used biologic therapy class, indicating that mAbs have become a highly popular choice for patients. Unfortunately, mAb therapies are expensive, typically costing tens of thousands of euros per patient and are between three and 300 times more expensive than comparable small molecule therapies [ 2 ]. One reason for these high costs is the large dose volume needed to achieve clinical efficacy and ...